Related Experiment Video

Updated: Nov 10, 2025

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors
04:36

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors

Published on: October 17, 2025

457

BETing on rational combination therapy in mutant FLT3 acute myeloid leukemia

Richard M Stone1

  • 1Leukemia Division, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA. rstone@partners.org.

Haematologica
|April 1, 2021
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

425
Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype
14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

3.4K

Related Experiment Videos

Last Updated: Nov 10, 2025

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors
04:36

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors

Published on: October 17, 2025

457
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

425
Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype
14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

3.4K

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.5K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K

Articles linked to this work by shared authors, journal, and citation graph.

Epigenetic markers expand genetic risk estimation in acute myeloid leukemia.

Blood·2026

A novel combination approach targeting P300 and DNA-PK exploits epigenetic dependencies in acute myeloid leukemia.

Molecular therapy. Oncology·2026

A Phase Ib/II study of ceralasertib, a selective inhibitor of ATR, in patients with relapsed or refractory MDS and CMML.

Blood advances·2026

Dual CDK2 and CDK4/6 inhibition suppresses Rb/E2F signaling and enhances anti-leukemic activity in acute myeloid leukemia.

Haematologica·2026

NCCN Guidelines® Insights: Acute Myeloid Leukemia, Version 3.2026.

Journal of the National Comprehensive Cancer Network : JNCCN·2026

Prognostic and therapeutic implications of BRAF mutations in acute myeloid leukemia.

Leukemia·2026

Cusatuzumab combined with venetoclax with or without azacitidine in unfit patients with newly diagnosed acute myeloid leukemia: phase Ib ELEVATE study.

Haematologica·2026

Surveying survival: benchmarking acute myeloid leukemia outcomes without transplant.

Haematologica·2026

Measurable residual KMT2A partial tandem duplication before allogeneic stem cell transplantation in acute myeloid leukemia.

Haematologica·2026

Normal platelet function in a patient with ARHGEF1 deficiency.

Haematologica·2026

Bone marrow biopsy characteristics at nadir after intensive induction therapy do not predict outcomes in adult acute myeloid leukemia patients: an analysis of ECOG-ACRIN clinical trials.

Haematologica·2026

Efficacy and safety of bridging therapy prior to CAR T-cell therapy in relapsed or refractory multiple myeloma.

Haematologica·2026

How Much Dissection Is Enough? Mesenteric Vessel Skeletonization Length and Lymph Node Harvest Quality in Rectal Cancer Surgery.

The American surgeon·2026

Follicular lymphoma and the microenvironment: potential targets and biomarkers.

Expert review of clinical immunology·2026

Histotripsy for Hepatocellular Carcinoma: From Bench to Bedside.

Radiology·2026

Targeting the HEC1-NEK2 Axis Suppresses DLBCL Progression and Overcomes Vincristine Resistance.

Molecular cancer therapeutics·2026

KSHV promotes leukocyte adhesion and transendothelial migration via induction of VCAM1.

mBio·2026

Bufalin Inhibits Melanoma Progression and Endothelial Angiogenic Phenotypes via AKT Signaling.

Cancer reports (Hoboken, N.J.)·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us